dementia-2017-scientifictracks-abstracts

30 / 31

Page 53
Notes:
conferenceseries.com
Volume 7, Issue 6 (Suppl) J Alzheimers Dis Parkinsonism, an open access journal
ISSN: 2161-0460 Dementia 2017
October 16-18, 2017
ALZHEIMER’S DISEASE & DEMENTIA
October 16-18, 2017 | Rome, Italy
9th International Conference on
Efficacy and safety of MMFS-01, a synapse density enhancer, for reversing age-related cognitive
decline: A randomized, double-blind, placebo-controlled trial
Guosong Liu
Tsinghua University, China
Background: Age-related cognitive decline is a major problem in elderly, affecting quality of life. Pre-clinical studies show that
MMFS-01, a synapse density enhancer, is effective at reversing cognitive decline in aging rodents.
Objective: Since brain atrophy during aging is strongly associated with both cognitive decline and sleep disorder, we evaluated
the efficacy of MMFS-01 in its ability to reverse cognitive decline and improve sleep.
Methods: We conducted a randomized, double-blind, placebo-controlled, parallel-designed trial in elderly subjects (age 50-
70) with complaints of memory impairment, sleep disorder, and anxiety. Subjects were treated with MMFS-01 (n=23) or
placebo (n=21) for 12 weeks and cognitive ability, sleep quality, and emotion were evaluated. Overall cognitive ability was
determined by a composite score of tests in four major cognitive domains.
Results: With MMFS-01 treatment, overall cognitive ability improved significantly relative to placebo (p=0.002; Cohen's
d=0.92). Age-related cognitive fluctuation was also reduced. Although the study population had more severe executive
function deficits than age-matched controls, MMFS-01 treatment nearly restored impaired executive function, demonstrating
that MMFS-01 was clinically significant. Sleep quality and anxiety were improved in MMFS-01 treatment group; however,
similar degrees of improvement were also observed in the placebo control group.
Conclusions: The current study demonstrates the potential of MMFS-01 for treating age-related cognitive decline in elderly.
Biography
Guosong Liu received his PhD in Physiological Sciences from the University of California, Los Angeles in 1990. He completed post-doctoral scientific training at
Stanford University and then went on to a faculty position at Massachusetts Institute of Technology. Liu continued a vigorous scientific research program at Tsinghua
University, and leads and oversee - as CEO - the multiple clinical development programs of Neurocentria. Dr. Liu is a world renowned expert in synaptic physiology,
learning, and memory. His research focuses primarily on discovering principles that regulate synapse density in the brain under physiological and pathological
conditions and developing novel strategies for treating neurodegeneration and preventing brain atrophy.
Guosong Liu, J Alzheimers Dis Parkinsonism 2017, 7:6(Suppl)
DOI: 10.4172/2161-0460-C1-033